
© 2024 Der Aktionär
Realtime | Geld | Brief | Zeit |
---|---|---|---|
3,670 | 3,730 | 01.04. | |
3,662 | 3,744 | 01.04. |
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Di | Cantor Fitzgerald maintains overweight on Immatics stock | ||
Do | Immatics GAAP EPS of €0.14 beats, revenue of $161.9M | ||
Do | Immatics N.V. - 6-K, Report of foreign issuer | ||
Do | Immatics Announces Full Year 2024 Financial Results and Business Update | Randomized-controlled Phase 3 trial, SUPRAME, to evaluate ACTengine® IMA203 TCR-T (PRAME) in advanced melanoma patients; first patient randomized and enrollment continues as plannedACTengine® IMA203... ► Artikel lesen | |
Do | Immatics N.V. - 20-F, Annual and transition report of foreign private issuers |